ArticleBioanalysis2025
Development and validation of a bioanalytical method to quantify povorcitinib in human skin with clinical application.
Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimQuantification of drug concentrations in human skin is essential for understanding mechanisms of action in dermatologic therapeutics but remains analytically challenging. The study aimed to develop and validate a standardized tissue homogenization and liquid chromatography - tandem mass spectrometry workflow for quantifying povorcitinib in human skin biopsies. MATERIALS &
methodsKey skin homogenization parameters, including solvent composition, processing volume, and homogenate density, were systematically evaluated. Wet and dry homogenization approaches were compared. Following protein precipitation, samples were analyzed using liquid chromatography - tandem mass spectrometry.
resultsEighteen solvent systems and various processing volumes were evaluated, with three solvent mixtures producing homogeneous preparations. Limiting homogenization volumes to less than half tube capacity and using 20 mg/mL improved sample consistency. Povorcitinib stability under acidic and thermal conditions was confirmed. Comparable performance was observed between wet and dry homogenization methods, and a dry workflow was validated.
conclusionsThis study provides the first systemic evaluation of human skin homogenization parameters and a direct comparison of wet and dry approaches. The validated dry homogenization method enabled accurate and reproducible quantification of povorcitinib in skin biopsies from a phase I clinical study and offers a robust framework for quantifying a broad range of analytes in human skin tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.